Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276

1.

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.

Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M.

Diabetes Care. 2019 Jun;42(6):1147-1154. doi: 10.2337/dc18-2316. Epub 2019 Feb 6. Review.

PMID:
30728224
2.

A Pilot Study to Assess Clinical Utility and User Experience of Professional Continuous Glucose Monitoring Among People With Type 2 Diabetes.

Midyett K, Unger JR, Wright EE, Daniel TD, Kruger DF, Henry RR, Hegazi RA.

Clin Diabetes. 2019 Jan;37(1):57-64. doi: 10.2337/cd18-0006.

PMID:
30705498
3.

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.

Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, Sunny NE, Kalavalapalli S, Pettus J, Ciaraldi TP, Mudaliar S, Henry RR.

Diabetes Obes Metab. 2018 Nov 16. doi: 10.1111/dom.13584. [Epub ahead of print]

PMID:
30447037
4.

Correction to: Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance.

Formentini L, Ryan AJ, Gálvez-Santisteban M, Carter L, Taub P, Lapek JD Jr, Gonzalez DJ, Villarreal F, Ciaraldi TP, Cuezva JM, Henry RR.

Diabetologia. 2018 Dec;61(12):2674. doi: 10.1007/s00125-018-4747-3.

PMID:
30324489
5.

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.

Henry RR, Frias JP, Walsh B, Skare S, Hemming J, Burns C, Bicsak TA, Baron A, Fineman M.

PLoS One. 2018 Sep 25;13(9):e0203946. doi: 10.1371/journal.pone.0203946. eCollection 2018.

6.

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.

Henry RR, Strange P, Zhou R, Pettus J, Shi L, Zhuplatov SB, Mansfield T, Klein D, Katz A.

Diabetes Technol Ther. 2018 Nov;20(11):715-724. doi: 10.1089/dia.2018.0052. Epub 2018 Sep 14.

7.

SGLT inhibitor adjunct therapy in type 1 diabetes.

McCrimmon RJ, Henry RR.

Diabetologia. 2018 Oct;61(10):2126-2133. doi: 10.1007/s00125-018-4671-6. Epub 2018 Aug 22. Review.

8.

Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.

Schrieks IC, Nozza A, Stähli BE, Buse JB, Henry RR, Malmberg K, Neal B, Nicholls SJ, Rydén L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG.

Diabetes Care. 2018 Aug;41(8):1792-1800. doi: 10.2337/dc18-0158. Epub 2018 Jun 14.

9.

Uromodulin mRNA from Urinary Extracellular Vesicles Correlate to Kidney Function Decline in Type 2 Diabetes Mellitus.

Yamamoto CM, Murakami T, Oakes ML, Mitsuhashi M, Kelly C, Henry RR, Sharma K.

Am J Nephrol. 2018;47(5):283-291. doi: 10.1159/000489129. Epub 2018 May 18.

PMID:
29779026
10.

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.

Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN.

Diabetes Obes Metab. 2018 Jul;20(7):1632-1641. doi: 10.1111/dom.13273. Epub 2018 Mar 25.

11.

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry RR, Tinahones FJ, Bujas-Bobanovic M, Domenger C, Letierce A, Samuel R, Del Prato S.

Diabetes Obes Metab. 2018 Jun;20(6):1479-1489. doi: 10.1111/dom.13257. Epub 2018 Mar 23.

12.

Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study.

Henry RR, Rosenstock J, Denham DS, Prabhakar P, Kjems L, Baron MA.

Diabetes Care. 2018 Mar;41(3):613-619. doi: 10.2337/dc17-1519. Epub 2018 Jan 4.

PMID:
29301824
13.

Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial.

Pettus J, Reeds D, Cavaiola TS, Boeder S, Levin M, Tobin G, Cava E, Thai D, Shi J, Yan H, Bautista E, McMillan J, Unger R, Henry RR, Klein S.

Diabetes Obes Metab. 2018 May;20(5):1302-1305. doi: 10.1111/dom.13202. Epub 2018 Jan 22.

14.

A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints.

Moreno-Ulloa A, Nájera-García N, Hernández M, Ramírez-Sánchez I, Taub PR, Su Y, Beltrán-Partida E, Ceballos G, Dugar S, Schreiner G, Best BM, Ciaraldi TP, Henry RR, Villarreal F.

Food Funct. 2018 Jan 24;9(1):307-319. doi: 10.1039/c7fo01028a.

15.

Circulating ApoJ is closely associated with insulin resistance in human subjects.

Seo JA, Kang MC, Ciaraldi TP, Kim SS, Park KS, Choe C, Hwang WM, Lim DM, Farr O, Mantzoros C, Henry RR, Kim YB.

Metabolism. 2018 Jan;78:155-166. doi: 10.1016/j.metabol.2017.09.014. Epub 2017 Oct 3.

16.

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.

Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, Mandel J, Samuel R, Henry RR.

Diabetes Obes Metab. 2017 Dec;19(12):1781-1792. doi: 10.1111/dom.13114. Epub 2017 Oct 10.

17.

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.

Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Simó R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P.

N Engl J Med. 2017 Dec 14;377(24):2337-2348. doi: 10.1056/NEJMoa1708337. Epub 2017 Sep 13.

18.

Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance.

Formentini L, Ryan AJ, Gálvez-Santisteban M, Carter L, Taub P, Lapek JD Jr, Gonzalez DJ, Villarreal F, Ciaraldi TP, Cuezva JM, Henry RR.

Diabetologia. 2017 Oct;60(10):2052-2065. doi: 10.1007/s00125-017-4379-z. Epub 2017 Aug 2. Erratum in: Diabetologia. 2018 Oct 15;:.

19.

Deletion of interleukin 1 receptor-associated kinase 1 (Irak1) improves glucose tolerance primarily by increasing insulin sensitivity in skeletal muscle.

Sun XJ, Kim SP, Zhang D, Sun H, Cao Q, Lu X, Ying Z, Li L, Henry RR, Ciaraldi TP, Taylor SI, Quon MJ.

J Biol Chem. 2017 Jul 21;292(29):12339-12350. doi: 10.1074/jbc.M117.779108. Epub 2017 Jun 1.

20.

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

Müller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M.

Cardiovasc Diabetol. 2017 May 25;16(1):70. doi: 10.1186/s12933-017-0552-4.

21.

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

Cariou B, Leiter LA, Müller-Wieland D, Bigot G, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Letierce A, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M.

Diabetes Metab. 2017 Oct;43(5):453-459. doi: 10.1016/j.diabet.2017.01.004. Epub 2017 Mar 24.

22.

Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.

Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L.

Diabetes Obes Metab. 2017 Jun;19(6):814-821. doi: 10.1111/dom.12882. Epub 2017 Mar 27.

PMID:
28098426
23.

Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.

Mudaliar S, Henry RR, Ciaraldi TP, Armstrong DA, Burke PM, Pettus JH, Garhyan P, Choi SL, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen NK, Sinha VP, Linnebjerg H, Jacober SJ.

Diabetes Obes Metab. 2016 Oct;18 Suppl 2:17-24. doi: 10.1111/dom.12753.

PMID:
27723226
24.

Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.

Espinoza SE, Wang CP, Tripathy D, Clement SC, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Stentz FB, Reaven PD, DeFronzo RA, Musi N.

Age (Dordr). 2016 Dec;38(5-6):485-493. doi: 10.1007/s11357-016-9946-6. Epub 2016 Sep 1.

25.
26.

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors.

Polonsky WH, Henry RR.

Patient Prefer Adherence. 2016 Jul 22;10:1299-307. doi: 10.2147/PPA.S106821. eCollection 2016. Review.

27.

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.

Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, Müller-Wieland D, Henry RR, Cariou B, Baccara-Dinet MT, Pordy R, Merlet L, Eckel RH.

Eur Heart J. 2016 Oct 14;37(39):2981-2989. Epub 2016 Jul 26.

28.

Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes.

Ciaraldi TP, Ryan AJ, Mudaliar SR, Henry RR.

PLoS One. 2016 Jul 25;11(7):e0158209. doi: 10.1371/journal.pone.0158209. eCollection 2016.

29.

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.

Mudaliar S, Alloju S, Henry RR.

Diabetes Care. 2016 Jul;39(7):1115-22. doi: 10.2337/dc16-0542.

PMID:
27289124
30.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.

Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR.

Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.

PMID:
27082665
31.

Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.

Peters AL, Henry RR, Thakkar P, Tong C, Alba M.

Diabetes Care. 2016 Apr;39(4):532-8. doi: 10.2337/dc15-1995.

PMID:
26989182
32.

Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.

Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA.

J Clin Endocrinol Metab. 2016 May;101(5):2056-62. doi: 10.1210/jc.2015-4202. Epub 2016 Mar 16.

33.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE).

Endocr Pract. 2016 Jan;22(1):84-113. doi: 10.4158/EP151126.CS. No abstract available.

PMID:
26731084
34.

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.

Mudaliar S, Polidori D, Zambrowicz B, Henry RR.

Diabetes Care. 2015 Dec;38(12):2344-53. doi: 10.2337/dc15-0642. Review.

PMID:
26604280
35.

Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management "Tune Up" Clinic in Complex Patients.

Morello CM, Christopher ML, Ortega L, Khoan J, Rotunno T, Edelman SV, Henry RR, Hirsch JD.

Ann Pharmacother. 2016 Jan;50(1):8-16. doi: 10.1177/1060028015615586. Epub 2015 Nov 5.

PMID:
26546580
36.

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.

Henry RR, Thakkar P, Tong C, Polidori D, Alba M.

Diabetes Care. 2015 Dec;38(12):2258-65. doi: 10.2337/dc15-1730. Epub 2015 Oct 20.

PMID:
26486192
37.

Activation of G proteins by GIV-GEF is a pivot point for insulin resistance and sensitivity.

Ma GS, Lopez-Sanchez I, Aznar N, Kalogriopoulos N, Pedram S, Midde K, Ciaraldi TP, Henry RR, Ghosh P.

Mol Biol Cell. 2015 Nov 15;26(23):4209-23. doi: 10.1091/mbc.E15-08-0553. Epub 2015 Sep 16.

38.

Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes.

Eckel RH, Henry RR, Yue P, Dhalla A, Wong P, Jochelson P, Belardinelli L, Skyler JS.

Diabetes Care. 2015 Jul;38(7):1189-96. doi: 10.2337/dc14-2629. Epub 2015 Jun 6.

39.

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes.

Inzucchi SE, Nauck MA, Hehnke U, Woerle HJ, von Eynatten M, Henry RR.

Diabetes Obes Metab. 2015 Sep;17(9):868-77. doi: 10.1111/dom.12490. Epub 2015 Jun 27. Review.

PMID:
25974030
40.

Excessive secretion of IL-8 by skeletal muscle in type 2 diabetes impairs tube growth: potential role of PI3K and the Tie2 receptor.

Amir Levy Y, Ciaraldi TP, Mudaliar SR, Phillips SA, Henry RR.

Am J Physiol Endocrinol Metab. 2015 Jul 1;309(1):E22-34. doi: 10.1152/ajpendo.00513.2014. Epub 2015 May 5.

41.

Treatment for Type 2 Diabetes.

Juang PS, Henry RR.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2013 Sep 4.

42.

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015.

Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovič L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F.

Endocr Pract. 2015 Apr;21 Suppl 1:1-87. doi: 10.4158/EP15672.GL. No abstract available.

43.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY.

Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovič L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F.

Endocr Pract. 2015 Apr;21(4):413-37. No abstract available.

PMID:
27408942
44.

Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.

Henry RR, Buse JB, Wu H, Durrwell L, Mingrino R, Jaekel K, El Azzouzi B, Andjelkovic M, Herz M.

Diabetes Obes Metab. 2015 Jun;17(6):560-565. doi: 10.1111/dom.12455. Epub 2015 Apr 8.

PMID:
25728612
45.

A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.

Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Reaven PD, Musi N, Ferrannini E, DeFronzo RA.

J Clin Endocrinol Metab. 2015 May;100(5):1855-62. doi: 10.1210/jc.2014-3824. Epub 2015 Jan 20.

46.

Type 2 diabetes mellitus.

DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R.

Nat Rev Dis Primers. 2015 Jul 23;1:15019. doi: 10.1038/nrdp.2015.19. Review.

PMID:
27189025
47.

Regulation of substrate utilization by the mitochondrial pyruvate carrier.

Vacanti NM, Divakaruni AS, Green CR, Parker SJ, Henry RR, Ciaraldi TP, Murphy AN, Metallo CM.

Mol Cell. 2014 Nov 6;56(3):425-35. doi: 10.1016/j.molcel.2014.09.024. Epub 2014 Oct 30.

48.

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.

Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, Bogle A, Iqbal N, List J, Griffen SC.

Diabetes Care. 2015 Mar;38(3):412-9. doi: 10.2337/dc13-2955. Epub 2014 Sep 30.

PMID:
25271207
49.

Status of Diabetes Care: "It just doesn't get any better . . . or does it?".

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry RR, Hill Golden S, Rich S, Reynolds L.

Diabetes Care. 2014 Jul;37(7):1782-5. No abstract available.

50.

Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.

Henry RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H.

Diabetes Care. 2014 Sep;37(9):2609-15. doi: 10.2337/dc14-0210. Epub 2014 Jun 19.

PMID:
24947791

Supplemental Content

Loading ...
Support Center